| Literature DB >> 24566440 |
Phillip G Bell1, Ian H Walshe2, Gareth W Davison3, Emma Stevenson4, Glyn Howatson5.
Abstract
This investigation examined the impact of Montmorency tart cherry concentrate (MC) on physiological indices of oxidative stress, inflammation and muscle damage across 3 days simulated road cycle racing. Trained cyclists (n = 16) were divided into equal groups and consumed 30 mL of MC or placebo (PLA), twice per day for seven consecutive days. A simulated, high-intensity, stochastic road cycling trial, lasting 109 min, was completed on days 5, 6 and 7. Oxidative stress and inflammation were measured from blood samples collected at baseline and immediately pre- and post-trial on days 5, 6 and 7. Analyses for lipid hydroperoxides (LOOH), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), interleukin-1-beta (IL-1-β), high-sensitivity C-reactive protein (hsCRP) and creatine kinase (CK) were conducted. LOOH (p < 0.01), IL-6 (p < 0.05) and hsCRP (p < 0.05) responses to trials were lower in the MC group versus PLA. No group or interaction effects were found for the other markers. The attenuated oxidative and inflammatory responses suggest MC may be efficacious in combating post-exercise oxidative and inflammatory cascades that can contribute to cellular disruption. Additionally, we demonstrate direct application for MC in repeated days cycling and conceivably other sporting scenario's where back-to-back performances are required.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24566440 PMCID: PMC3942735 DOI: 10.3390/nu6020829
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Schematic of testing protocol. Trials took place on consecutive days at 8:00 am following an overnight fast.
Simulated road cycling race protocol (Vaile et al., 2008) [29]. Work—Maximal effort sprint. Rest—Power at 40%–50% Wmax. ACT (Active recovery)-Power at 40%–50% Wmax. TT (Time Trial)—Sustained maximal effort.
| 10 minute warm up (Self-selected pace) | ||
|---|---|---|
| Set Number | Sprint Frequency/Duration | Work to Rest Ratio |
| Set 1 | 12 × 5 s | 1:6 (Work:Rest) |
| Set 2 | 12 × 5 s | 1:3 (Work:Rest) |
| Set 3 | 12 × 5 s | 1:1 (Work:Rest) |
| 4 min ACT- | ||
| Set 4 | 6 × 10 s | 1:6 (Work:Rest) |
| Set 5 | 6 × 10 s | 1:3 (Work:Rest) |
| Set 6 | 6 × 10 s | 1:1 (Work:Rest) |
| 4 min ACT- | ||
| Set 7 | 4 × 15 s | 1:6 (Work:Rest) |
| Set 8 | 4 × 15 s | 1:3 (Work:Rest) |
| Set 9 | 4 × 15 s | 1:1 (Work:Rest) |
| 5 min ACT- | ||
Figure 2Serum lipid hydroperoxide responses (% Change from baseline) to Montmorency cherry concentrate (MC) and isoenergetic placebo (PLA). Absolute baseline values were 1.269 ± 0.085 and 1.189 ± 0.153 mmol mL−1 for MC and PLA respectively. * Significant group effect (p < 0.05), $ Significant interaction effect (p < 0.05); values are mean ± SD.
Figure 3Plasma interleukin-6 responses (pg·mL−1) to Montmorency cherry concentrate (MC) and isoenergetic placebo (PLA). * Significant group effect (p < 0.05), $ Significant interaction effects (p < 0.05); values are mean ± SD.
Figure 4High-sensitivity CRP responses (% Change from baseline) to Montmorency cherry concentrate (MC) and isoenergetic placebo (PLA). Absolute baseline values were 0.889 ± 0.592 and 0.475 ± 0.191 pg·mL−1 for MC and PLA respectively. * Significant group effect (p < 0.05), $ Significant interaction effects (p < 0.05); values are mean ± SD.
Markers of inflammation and muscle damage not different between groups.
| Baseline | Pre-trial 1 | Post-trial 1 | Pre-trial 2 | Post-trial 2 | Pre-trial 3 | Post-trial 3 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| IL-1-β (pg mL−1) | ||||||||||||||
| MC | 0.09 | 0.15 | 0.10 | 0.17 | 0.06 | 0.08 | 0.05 | 0.09 | 0.14 | 0.20 | 0.10 | 0.15 | 0.08 | 0.12 |
| PLA | 0.27 | 0.47 | 0.11 | 0.14 | 0.20 | 0.22 | 0.20 | 0.29 | 0.19 | 0.29 | 0.16 | 0.20 | 0.13 | 0.18 |
| IL-8 (pg mL−1) * | ||||||||||||||
| MC | 2.34 | 0.96 | 2.67 | 0.95 | 4.75 | 0.63 | 2.68 | 0.95 | 3.68 | 1.35 | 2.39 | 1.07 | 3.76 | 1.42 |
| PLA | 3.21 | 1.30 | 3.20 | 1.22 | 5.30 | 2.14 | 2.94 | 0.92 | 4.07 | 1.12 | 2.76 | 1.04 | 3.86 | 1.11 |
| TNF-α (pg mL−1) | ||||||||||||||
| MC | 1.66 | 0.52 | 1.50 | 0.49 | 1.91 | 0.58 | 1.66 | 0.58 | 1.51 | 0.56 | 1.50 | 0.58 | 1.70 | 0.40 |
| PLA | 1.87 | 0.85 | 1.64 | 0.71 | 1.94 | 0.72 | 1.65 | 0.86 | 1.62 | 0.85 | 1.64 | 0.79 | 1.76 | 0.81 |
| CK (IU/L) * | ||||||||||||||
| MC | 146.0 | 57.2 | 146.0 | 57.2 | 245.8 | 96.3 | 206.0 | 120.7 | 188.0 | 83.1 | 224.3 | 100.4 | 169.0 | 65.1 |
| PLA | 128.7 | 74.0 | 128.7 | 74.0 | 180.4 | 77.0 | 279.3 | 310.8 | 222.7 | 91.6 | 287.0 | 153.6 | 292.7 | 231.3 |
*: Significant main effect for time (p < 0.05); IL-1-β: Interleukin-1-beta; IL-8: Interleukin-8; TNF-α: Tumour Necrosis Factor-Alpha; CK: Creatine Kinase.
Time trial data.
| Trial 1 | Trial 2 | Trial 3 | ||||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | |
| Heart Rate (b·min−1) | ||||||
| MC | 160.89 | 21.32 | 162.01 | 24.90 | 159.09 | 22.29 |
| PLA | 158.45 | 18.63 | 160.84 | 21.11 | 159.70 | 20.12 |
| Work Performed (kJ) * | ||||||
| MC | 151.90 | 29.49 | 148.40 | 30.03 | 139.19 | 29.64 |
| PLA | 145.35 | 39.05 | 141.71 | 39.84 | 139.79 | 38.47 |
*: Significant main effect for time (p < 0.05).